Cargando…

Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib

The dysregulation of cyclin D -Cyclin-dependent kinase 4/6 (CDK4/6)-Rb axis has been implicated in breast cancer progression and the selective CDK4/6 inhibitors have shown effective activity in advanced breast cancer, especially in tumors driven by the estrogen receptor (ER). However, resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Wenfei, Shi, Yaqin, Wang, Xin, He, Weiwei, Tang, Lin, Tian, Shengwang, Jiang, Hua, Shu, Yongqian, Guan, Xiaoxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367574/ https://www.ncbi.nlm.nih.gov/pubmed/30745839 http://dx.doi.org/10.7150/ijbs.30572

Ejemplares similares

MEK blockade overcomes the limited activity of palbociclib in head and neck cancer
por: Fang, Zhenghuan, et al.
Publicado: (2020)

c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
por: Ji, Wenfei, et al.
Publicado: (2020)

Differential microRNA expression is associated with androgen receptor expression in breast cancer
por: Shi, Yaqin, et al.
Publicado: (2017)

Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance
por: Zheng, Wenxin, et al.
Publicado: (2016)

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors()
por: Shi, Yaqin, et al.
Publicado: (2019)

Therapeutic landscape in mutational triple negative breast cancer
por: Shi, Yaqin, et al.
Publicado: (2018)

Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017)

Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers
por: Tien, Amy H., et al.
Publicado: (2022)

Combinations using checkpoint blockade to overcome resistance
por: Morganti, Stefania, et al.
Publicado: (2020)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
por: Jin, Juan, et al.
Publicado: (2018)

Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase
por: Pandey, Kamal, et al.
Publicado: (2022)

Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade
por: Lassche, Gerben, et al.
Publicado: (2021)

Predicting castration-resistant prostate cancer after combined androgen blockade
por: He, Miao, et al.
Publicado: (2017)

A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma
por: Fushimi, C, et al.
Publicado: (2018)

BCL11A confers cell invasion and migration in androgen receptor-positive triple-negative breast cancer
por: Wang, Xin, et al.
Publicado: (2020)

Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia
por: Zee, Barry M., et al.
Publicado: (2021)

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
por: Zhou, Xiaoting, et al.
Publicado: (2022)

ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1
por: Song, Wei, et al.
Publicado: (2017)

Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein
por: Hernandez Maganhi, Stella, et al.
Publicado: (2017)

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors
por: Radaeva, Mariia, et al.
Publicado: (2022)

Orchiectomy or androgen receptor blockade attenuates baroreflex-mediated bradycardia in conscious rats
por: Ward, Gregg R, et al.
Publicado: (2006)

Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents
por: Zhang, Guanyi, et al.
Publicado: (2015)

Androgen receptor blockade using flutamide skewed sex ratio of litters in mice
por: Gharagozlou, Faramarz, et al.
Publicado: (2016)

BMP receptor blockade overcomes extrinsic inhibition of remyelination and restores neurovascular homeostasis
por: Petersen, Mark A, et al.
Publicado: (2021)

Updates on managing advanced breast cancer with palbociclib combination therapy
por: McShane, Teresa M., et al.
Publicado: (2018)

The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma
por: Horbinski, Craig, et al.
Publicado: (2021)

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
por: Kregel, Steven, et al.
Publicado: (2020)

Maximal androgen blockade for advanced prostate cancer
por: Mukha, Rajiv Paul, et al.
Publicado: (2010)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade
por: Yokomizo, Yumiko, et al.
Publicado: (2016)

Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer
por: Kim, Chang Woo, et al.
Publicado: (2021)

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
por: Lückerath, Katharina, et al.
Publicado: (2018)

Palbociclib-Induced Liver Failure
por: Atallah, Rami, et al.
Publicado: (2020)

Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report
por: Nersesjan, Vardan, et al.
Publicado: (2019)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
por: Klein, Florian G., et al.
Publicado: (2021)

The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer
por: Li, Liuxun, et al.
Publicado: (2022)

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E)
por: Antonello, Zeus A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cjku83201u8vtuia4b4uoips55